Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

123
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

04/19/2012 | 01:50pm US/Eastern
Recommend:
0

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Recommend :
0
React to this article
Latest news on MERCK & CO., INC.
2d ago MERCK : Announces First Presentation of Early Data on the Investigational Use of..
3d ago MERCK : Announces First Presentation of Data on the Investigational Use of KEYTR..
5d ago DOW MOVERS : Mrk, nke
7d ago MERCK : Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildr..
7d ago MERCK : Researchers at Merck & Company Target Toxicology (Considerations for con..
7d ago Adaptimmune raises $104 million to develop immune-system cancer drugs
7d ago MERCK : New Clinical Trials and Studies Study Findings Have Been Reported by Inv..
7d ago MERCK : to Hold Third-Quarter 2014 Sales and Earnings Conference Call on October..
7d ago MERCK : Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an In..
09/22 MERCK : Sun Pharma and Merck & Co. Ink Licensing Pact for Tildrakizumab
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF